Research News

Screening High-Risk Women Catches More Early Stage Ovarian Cancers

(March 15, 2017) Results from a large study showed that screening for ovarian cancer in high-risk patients led to detection of significantly more early-stage disease as compared with the year after screening ended…

Read on

Hormone Therapy Improves Survival of Low Grade Serous Carcinoma Patients

(March 6, 2017) A team from University of Texas MD Anderson Cancer Center, including OCRFA Scientific Advisory Committee Member Dr…

Read on

OCRFA Research Finds New Gene Mutation Spurs Cancer Growth

(February 7, 2017) An OCRFA funded study, published on January 13, 2017 in Oncotarget, sheds light on EMSY, a gene that researchers at New York University Langone Medical Center now understand to have a role similar to those of BRCA1 and BRCA2…

Read on

Rucaparib Extends PFS in Ovarian Cancer

(February 3, 2017) Results from the ARIEL2 trial, funded in part by OCRFA’s grant to the Stand Up to Cancer Ovarian Cancer Dream Team, were recently published in The Lancet…

Read on

OCRFA Funded Research Studies DNA Repair in Ovarian Cancer Cells

(January 30, 2017) In a study funded in part by OCRFA, and published this month in Oncotarget, researchers, including first author and former OCRFA grantee Petar Jelinic, PhD, studied EMSY, a putative BRCAness gene, and its role in the suppression…

Read on

Some Fallopian Tube Lesions Represent Ovarian Cancer Metastases, Not Precursor Lesions

(Dec…

Read on

Rucaparib FDA Approved for Advanced Ovarian Cancer with BRCA Mutations

(Dec. 19, 2016) The U.S. Food and Drug Administration today granted accelerated approval to Rubraca (rucaparib) to treat women with a certain type of ovarian cancer…

Read on

FDA Approves Avastin for Platinum-Sensitive Recurrent Ovarian Cancer

(Dec…

Read on

Managing Recurrence: What You Need to Know (Webinar Available)

Recurrence is in the back of every ovarian cancer survivor’s mind. In this presentation, originally broadcast on November 28, 2016, Dr…

Read on

OCRFA Funded Research Identifies Protein Group Responsible For Senescence’s Negative Side Effects

(Nov. 3, 2016) Senescence is the state when normal, healthy cells no longer have the ability to divide, which can occur during chemotherapy or when cancer genes within that cell are activated…

Read on

OCRFA Funded Study Explores New Role of Estrogen in Anti-Tumor Immunity

(October 31, 2016) Estrogen signaling is a known factor in how certain estrogen receptive (ER positive) tumors grow in breast and ovarian cancers…

Read on

OCRFA applauds FDA’s statement on ovarian cancer screening test

On September 7th, the FDA issued an important safety communication about tests marketed as ovarian cancer screening tests, including the ROCA Test developed by Abcodia Incorporated…

Read on